NeerajAgarwalMD

PubMed

• Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
  Eddy Saad, Georges Gebrael, Karl Semaan, Marc Eid, Renée Maria Saliby, Chris Labaki, Nicolas Sayegh, J Connor Wells, Kosuke Takemura, Matthew Scott Ernst, Audreylie Le...> ;The Oncologist. 2024 Apr 17
• CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
  Sumanta K Pal, Ben Tran, John B A G Haanen, Michael E Hurwitz, Adrian Sacher, Nizar M Tannir, Lihua E Budde, Simon J Harrison, Sebastian Klobuch, Sagar S Patel, Luis M...> ;Cancer Discovery. 2024 Apr 5
• Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer.
  Daniel J George, Krishnan Ramaswamy, Zachary Klaassen, David Russell, Rickard Sandin, Birol Emir, Hongbo Yang, Wei Song, Yilu Lin, Agnes Hong, Wei Gao, Stephen J Freed...> ;Prostate Cancer and Prostatic Diseases. 2024 Apr 2
• Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
  Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Nishita Tripathi, Beverly Chigarira, Divyam Goel, Blake Nordblad, Taylor R McFarland, Arshit Narang, Ayana Srivast...> ;The Prostate. 2024 Apr 1
• First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in ...
  Rana R McKay, Alicia K Morgans, Neal D Shore, Curtis Dunshee, Geeta Devgan, Neeraj Agarwal> ;Cancer Treatment Reviews. 2024 Mar 29
• Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...
  Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins, Jill Kolesar, Neeraj Agarwal, Rahul A Parikh, Daniel A Vaena, Christopher W Ryan, Mehmoo...> ;Journal of Clinical Oncology. 2024 Mar 26
• Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S...
  Mamta Parikh, Catherine Tangen, Maha H A Hussain, Shilpa Gupta, Sam Callis, Yeonjung Jo, Andrea Harzstark, Channing J Paller, Saby George, Matthew R Zibelman, Heather ...> ;European Urology Oncology. 2024 Mar 23
• A Signal-finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
  Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa, Jose Angel Arranz Arija, Emeline Colomba, Gwenaelle Gravis, Loic Mourey, Stephane Oudard, Aude Fléchon, Macare...> ;Clinical Cancer Research. 2024 Mar 21
• Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Prog...
  Wassim Abida, Andrew W Hahn, Neal Shore, Neeraj Agarwal, Paul Sieber, Matthew R Smith, Tanya Dorff, Paul Monk, Matthew Rettig, Rupal Patel, Anne Page, Maureen Duff, Ro...> ;Clinical Cancer Research. 2024 Mar 15
• A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
  Benson, M., Boucher, K., Sahu, K., Li, H., Mathew Thomas, V., Gupta, S., Kohli, M., Swami, U., Agarwal, N., Maughan, B.> ;The Oncologist. 2024 Mar 7
• Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III tria...
  Primo N Lara Jr, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twa...> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 29
• Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
  Mathew Thomas, V., Grivas, P., Agarwal, N.> ;Med. 2024 Feb 9
• NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
  Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
• Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
  Fizazi, K., Azad, A., Matsubara, N., Carles, J., Fay, A., De Giorgi, U., Joung, J., Fong, P., Voog, E., Jones, R., Shore, N., Dunshee, C., Zschäbitz, S., Oldenburg, J....> ;Nature Medicine. 2024 Jan 31
• Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
  Kripa Guram, Jiaming Huang, Christian Mouchati, Nour Abdallah, Chinmay Jani, Vishal Navani, Wanling Xie, Talal El Zarif, Elio Adib, Georges Gebrael, Neeraj Agarwal, Ha...> ;Cancer. 2024 Jan 31
• 1 citations
  Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Dat...
  Kosuke Takemura, Audreylie Lemelin, Matthew S Ernst, J Connor Wells, Renee Maria Saliby, Talal El Zarif, Chris Labaki, Naveen S Basappa, Bernadett Szabados, Thomas Pow...> ;European Urology. 2024 Jan 29
• 2 citations
  Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
  Jon Mahlow, Marc Barry, Daniel J Albertson, Yeon Jung Jo, Michael Balatico, Tori Seasor, Georges Gebrael, Shruti A Kumar, Nicolas Sayegh, Nishita Tripathi, Neeraj Agar...> ;Human Pathology. 2024 Feb 1
• Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 C...
  Petros Grivas, Damien Pouessel, Chandler H Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Fléchon, Chethan Ramamu...> ;Journal of Clinical Oncology. 2024 Apr 20
• Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer.
  Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal> ;Cancer Discovery. 2024 Jan 12
• Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
  Miller, E., Eric J Miller, Tracy L Rose, Benjamin L Maughan, Matthew I Milowsky, Mehmet A Bilen, Bradley C Carthon, Xin Gao, Suthee Rapisuwon, Qianqian Zhao, Menggang ...> ;Cancer. 2024 May 1
• Impact of Initial Timing of Metastatic Disease on Survival in Patients With Newly Diagnosed Metastatic Castration-Resistant Prostate Cancer Treated With Androgen Recep...
  Nicolas Sayegh, Nishita Tripathi, Divyam Goel, Taylor McFarland, Hedyeh Ebrahimi, Blake Nordblad, Beverly Chigarira, Kamal Kant Sahu, Haoran Li, Alexander Chehrazi-Raf...> ;Urology Practice. 2024 Jan 1
• Editorial Comment.
  Arshit Narang, Neeraj Agarwal> ;Urology Practice. 2024 Jan 1
• 6 citations
  Update on combined immunotherapy for the treatment of advanced renal cell carcinoma.
  Kamal Kant Sahu, Neeraj Agarwal, Benjamin L Maughan, Georges Gebrael> ;Human Vaccines & Immunotherapeutics. 2023 Dec 31
• Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cance...
  Simon Chowdhury, Anders Bjartell, Neeraj Agarwal, Byung H Chung, Robert W Given, Andrea J Pereira de Santana Gomes, Axel S Merseburger, Mustafa Özgüroğlu, Álvaro Juáre...> ;Future Oncology. 2024 Mar 1
• Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced P...
  Chi, K., Chowdhury, S., Bevans, K., Bhaumik, A., Saad, F., Chung, B., Oudard, S., De Porre, P., Brookman-May, S., McCarthy, S., Mundle, S., Uemura, H., Small, E., Kars...> ;European Urology Oncology. 2023 Dec 9
• Join now to see all

Journal Articles

• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer  
  Maha Hussain, Neeraj Agarwal, Przemyslaw Twardowski, The New England Journal of Medicine
• Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma  
  Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
• Immunologic Therapy of Renal Cell Carcinoma  
  Agarwal N, Fishman M, Oncology & Hematology Review, 1/1/2014
• Paradigm towards Tailored Therapies and Complete Responses in the Treatment of Metastatic Renal Cell Carcinoma  
  Fishman M, Hutson T, Agarwal N, Jonasch E, Oncology & Hematology Review, 1/1/2012
• Editorial comment on "a Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Prior to Radical Prostatectomy in High-Risk Patients"  
  Agarwal N, Journal of Urology, 1/1/2011
• Join now to see all

Books/Book Chapters

• Lost in Translation: Barriers in Incentives for Translational Research 
  Chapter: "Integrating Emerging Science into Clinical Practice: Targeting Androgen Signaling in Castration Resistant Metastatic Prostate Cancer" 
  Kollepara SS, Tantravahi SK, Batten J, Agarwal NEditors: Lopaczynski W, Srivastava R, and Maksymowicz W.World Scientific Publishing Co Pte. Ltd, Singapore2014
• Multidisciplinary Approach to Prostate Cancer 
  Chapter: "Metastatic Castrate Resistant Prostate cancer: Role of Androgen Signaling Inhibitors" 
  Poole A, Alva A, Batten JA, Agarwal NEditors: Dicker AP, Trabulsi EJ, Kelly WK.Demos Medical Publishing, New York2014
• Cancer Vaccines 
  Chapter: "Development of novel immune interventions for genitor-urinary cancers" 
  Agarwal N, Vogelzang NJEditors: Adrian Bot, Mihail Obrocea & Francesco Marincola.Informa Healthcare, London, UKEdition 1st,2011
• Williams Hematology 
  Chapter: Methemoglobinemia and Other Dyshemoglobinemias 
  Agarwal N, Prchal JTEditors: Kaushansky K, Lichtman M, Beutler E.McGraw-Hill, New YorkEdition 8th,2009
• Disorders of Hemoglobin. Genetics, Pathophysiology, and Clinical Management 
  Chapter: Dyshemoglobinemia 
  Agarwal N, Nagel RL, Prchal JTEditors: Steinberg MH, Forget BG, Higgs DR, Nagel RL.Cambridge University Press, New YorkEdition 2nd,2009
• Wintrobe's Clinical Hematology 
  Chapter: "Miscellaneous Causes of Thrombocytopenia" 
  Agarwal N, Rodgers GMEditors: Greer JP, Foerster J, Rodgers GM et al.Lippincott Williams & Wilkins (LWW)Edition 12th,2009
• Hypoxia and Circulation 
  Chapter: "Genetic Mechanisms Underlying Regulation of Hemoglobin Mass" 
  Agarwal N, Gordeuk VR, Prchal JTEditors: Roach RC, Wagner PD, and Hackett PH.Springer, New York2007
• Join now to see all

Abstracts/Posters

• Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with h...
  Merriman J, Parikh K, Tantravahi SK, Straubhar AM, Agarwal A, Sendilnathan A, Van Atta J, Batten J, Grossmann K, Samlowski W, Stenehjem D, Agarwal N, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Association of hand-foot syndrome (HFS), treatment dose reductions (TDRs), and outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with vasc...
  Bailey E, Tantravahi SK, Poole A, Wells C, Batten J, Merriman J, Stenehjem D, Agarwal N, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) + TAK-700 with ADT + bicalutamide in patients with newly diagnosed metastatic hor...
  Agarwal N, Tangen C, Hussain M, Lara Jr P, Higano C, Vaena D, MacVicar G, Li H, Crispino T, Quinn D, Vogelzang N, Thompson Jr I, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sens...
  Yu E, Tangen C, Higano C, Agarwal N, Pal SK, Alva AS, Heath E, Tat Lam E, Gupta S, Lilly M, Inoue Y, Chi K, Vogelzang N, Quinn D, Li H, Cheng H, Plymate S, Hussain M, ..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versu...
  Cheng H, Li H, Higano C, Tangen C, Agarwal N, Yan J, Vogelzang N, Hussain M, Thompson Jr I, Tewari M, Yu E, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-inv...
  Galsky M, Harshman L, Crabb S, Wong YN, Yu E, Chowdhury S, Powles T, Pal SK, Moshier E, Ladoire S, Hussain S, Agarwal N, Vaishampayan U, Recine F, Berthold D, Necchi A..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal...
  Albiges L, Xie W, Lee JL, Rini B, Srinivas S, Bjarnason G, Ernst S, Wood L, Vaishamayan U, Rha SH, Agarwal N, Yuasa T, Pal SK, Koutsoukos K, Fay AP, Preston M, Cho E, ..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer...
  Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono JS, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak P, Lee C, Tej..., J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Evaluation of pharmacokinetic (PK) drug-drug interactions (DDI) between trebananib (AMG 386) and paclitaxel (PTX) in patients (pts) with advanced solid tumors.
  Diamond JR, Agarwal N, Bowles D, Lam ET, Werner T, Wu B, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S, J Clin Oncol; ASCO Annual Meeting, Chicago, IL, May 30-June 3, 2014, 1/1/2014
• Clinical outcomes and survival of patients (pts) with sarcomatoid metastatic renal cell carcinoma (smRCC).
  Tantravahi SK, Stenehjem DD, Agarwal A, Kollepara SL, Batten JA, Ward M, Albertson D, Wang JF, Liu T, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Conditional survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD-IL2).
  Parikh K, Stenehjem DD, Sendilnathan A, Crispin H, VanAtta J, Batten JA, Sagesser D, GrossmannK, Samlowski W, Tantravahi SK, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• The association between rigors and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2).
  Batten JA, Samlowski W, Parikh K, Sendilnathan A, Van Atta J, Batten JA, Sagesser D, Grossmann K, Tantravahi SK, Stenehjem DD, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Clinical benefit (CB) of high dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).
  Agarwal N, Parikh K, Tantravahi SK, Crispin H, VanAtta J, Batten JA, Sagesser D, Grossmann K, Samlowski W, Stenehjem DD, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high dose interleukin-2 (HD IL-2).
  Stenehjem DD, Parikh K, Batten JA, VanAtta J, Crispin H, Sagesser D, Grossmann K, Tantravahi SK, Samlowski W, Agarwal N, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• The Effect of Prior Abiraterone (Abi) Use on the Efficacy of Enzalutamide (Enza) in Men with mCRPC.
  Cheng HH, Nadal R, Gulati R, Azad A, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery RB, Galsky MD, Chi KN, Antonara..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma.
  Tsao CK, Agarwal N, Apolo AB, Lee KM, Godbold JH, Oh WK, Galsky MD, J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Databa...
  Heng DY, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal N, Vaish..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• The international metastatic renal cell carcinoma database consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously t...
  Ko JJ, Xie W, Heng DY, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Harshman LC, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Bamias A, Wood L, Ernst DS, Agarwal ..., J Clin Oncol; Genitourinary Cancers Symposium, San Francisco, CA, January 30-February 1, 2014, 1/1/2014
• Physical activity and quality of life associations with telomere length among senior female cancer survivors enrolled in a Tai Chi Chih trial.
  Campo RA, Light KC, O'Connor K, Nakamura Y, Lipschitz D, LaStayo P, Agarwal N, & Kinney AY, Society of Behavioral Medicine (SBM) Annual Meeting, San Francisco, CA, 1/20/2013
• Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members.
  Campo RA, O'Connor K, LaStayo P, Light KC, Agarwal N, & Kinney AY, American Psychosomatic Society Annual Meeting, Miami, FL, 1/13/2013
• Effects of a 12-week Qigong intervention on fatigue and global distress in senior prostate cancer survivors and their family members.
  Campo RA, O'Connor K, LaStayo P, Light KC, Agarwal N, Kinney AY, American Psychosomatic Society (APS) Annual Meeting, Miami, FL, 1/13/2013
• Phase I Study of Histone Deacetylase Inhibitor Belinostat in Combination with Warfarin in Patients with Solid Tumors or Hematological Malignancies.
  Agarwal N, Wade M, Batten J, Davidson C, Sun SL, Sharma S, AACR Annual Meeting, Washington, DC, 1/8/2013
• Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
  Cannon-Albright LA, Teerlink CC, Agarwal N, AACR Annual Meeting, Washington, DC, 1/8/2013
• 18F-FDG and FLT PET for early prediction of response to Sunitinib in metastatic renal cell carcinoma.
  Zollinger L, Morton K, Agarwal N, Kadrmas D, Christian P, Beardmore B, Butterfield R, Hoffman J, Society of Nuclear Medicine & Molecular Imaging (SNMMI), 2013 60th Annual Meeting, Vancouver, BC, Canada, 1/8/2013
• First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).
  Yick D, Heng C, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Y..., J Clin Oncol; American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, May 31-Jun 4, 2013, 1/1/2013
• Join now to see all

Lectures

• TALAPRO-2: Part 2 (P2) of the placebo-controlled phase 3 study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant ... 
  2019 ASCO Annual Meeting - 6/1/2019

Other

• Perspective opinion on "Gleason score associated with time to development of neuroendocrine prostate cancer. Wang HT et al. J Clin Oncol. 2014 Oct 20;32(30):3383-90" 
  Agarwal N, HemOnc Today
  Helio.com
  1/30/2014
• "Beyond the abstract- Development of novel immune interventions for prostate cancer" 
  Agarwal N, Vogelzang NJ, UroToday
  UroToday.com
  1/15/2012
• Management of Thrombotic Microangiopathy with Underlying Malignancy. 
  Lim HY, Werner TL, Agarwal N, Rodgers GM, Review Series Oncology
  1/1/2008
• "Case of the Quarter: Society of Hematopathology" 
  Wada D, Agarwal N, Lim M
  http://socforheme.org/caseqtr.htm
  1/1/2005
• DRESS syndrome associated with cephalosporin therapy. 
  Hussain I, Agarwal N, E-Letter in British Medical Journal
  http://bmj.bmjjournals.com/cgi/eletters/326/7403/1377
  1/1/2003
• Join now to see all